Unicycive Therapeutics Inc. (UNCY)
UNCY trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2023-12-31, https://www.sec.gov/Archives/edgar/data/1766140/000121390025025828/0001213900-25-025828-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2023-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | UNCY on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001766140 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2023
| Line | Value |
|---|---|
| Revenue | $675K |
| Net income | -$30.5M |
| Operating income | -$20.8M |
| Net margin | -4525.0% |
| Operating margin | -3077.6% |
| Revenue growth | -29.0% |
| Cash | $9.7M |
| Total assets | $14.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 152.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-08-12 |
| Cash and burn | $44.2M cash; operating cash flow -$7.0M a quarter. | Report 2026-06-30 |
| Shares outstanding | 27,855,257 (2026-08-12); 17,661,698 a year earlier; 34,752,221 three years earlier. 3y figure adjusted for split (1-for-10 overall). | Cover page 2026-08-12 |
| Reverse splits, 3 years | 1; latest 1-for-10 on 2025-06-20 | Source 2025-06-20 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-06-05 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Grassi & Co., CPAs, P.C., Jericho, New York, United States | PCAOB Form AP 2026-04-01 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$1.7M | -$7.6M | $44.2M | No debt tags | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | Not filed | -$12.8M | -$6.2M | $37.4M | No debt tags | Needs four quarters | 10-Q 2026-08-12 |
| Q4 2025 2025-12-31 | Not filed | -$14.7M | -$8.0M | $29.2M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | Not filed | -$6.0M | -$6.0M | $42.7M | No debt tags | Needs four quarters | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$6.4M | -$8.4M | $22.3M | No debt tags | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | Not filed | $570K | -$8.9M | $19.8M | No debt tags | Needs four quarters | 10-Q 2026-08-12 |
| Q4 2024 2024-12-31 | Not filed | -$21.5M | -$6.5M | $26.1M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
| Q3 2024 2024-09-30 | Not filed | -$4.1M | -$9.3M | $32.3M | No debt tags | Needs four quarters | 10-Q 2025-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document REGISTRATION STATEMENT | S-3 | 2026-06-05 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-03-30 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-16 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-16 |
| Latest proxy CURRENT REPORT | DEFA14A | 2026-06-22 |
Source: SEC EDGAR submissions feed, 311 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | 0.0% |
| 1 month | -4.8% |
| 3 months | -34.3% |
| Year to date | -38.5% |
| 1 year | -33.4% |
| From 52-week high | -58.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CUE | Cue Biopharma Inc. | $14.10 | -12.53% | $102.4M |
| OGI | Organigram Global Inc. Common Shares | $0.7240 | -12.62% | $102.2M |
| ORGO | Organogenesis Holdings Inc. | $0.8031 | -0.86% | $104.2M |
| DERM | Journey Medical Corporation | $3.70 | -14.55% | $104.5M |
| CLLS | Cellectis S.A. | $1.04 | -11.86% | $104.5M |
| ADAG | Adagene Inc. | $1.60 | -6.43% | $105.7M |
| BGM | BGM Group Ltd. | $8.01 | +1.71% | $107.0M |
| FHTX | Foghorn Therapeutics Inc. | $1.79 | -13.53% | $107.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier